85%Confidence
0Views
FDASource
2026-03-23Date
Summary
Cipla's Nilotinib Capsules recall due to stability failures indicates potential quality control issues at manufacturing sites, which could impact patient safety and regulatory standing. This may lead to increased scrutiny from the FDA and affect Cipla's reputation in the US market for generic oncology drugs.
Actionable: Monitor Cipla's regulatory compliance updates and consider reviewing investment exposure to their US pharmaceutical operations.
AI Confidence: 85%
Data Points
firmCipla USA, Inc.
classificationClass III
statusOngoing
distributionU.S.A. Nationwide
productNilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now